Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant.
Gaetano CicchittoLorena CardilloClaudio de MartinisPaola SabatiniRosita MarchitielloGiovanna AbateAdele RovettiAntonietta CavalleraCamillo ApuzzoFrancesco FerrignoGiovanna FuscoPublished in: Viruses (2022)
There is a growing interest in using monoclonal antibodies (mAbs) in the early stages of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection to prevent disease progression. Little is known about the efficacy of mAbs against the delta variant of concern and its clinical presentations. We evaluated the effect of casirivimab/imdevimab treatment among five delta vaccine breakthrough patients. Symptomatic non-hospitalized vaccinated patients were submitted to nasopharyngeal swabs for the detection of SARS-CoV-2 and Next-Generation Sequencing (NGS). Blood analysis and chest Computed Tomography were also performed. A cocktail of casirivimab/imdevimab was administrated, and patients were monitored weekly. Clinical evolution was evaluated by the regression of the symptoms, negative results by real-time RT-PCR, and by the need of hospitalization: these aspects were considered as significant outcomes. In four cases, symptom reversion and viral load reduction were observed within 2 days and 7 days after mAbs treatment, respectively. Only one case, suffering from thymoma, was hospitalized 2 days later because of respiratory failure, which reverted within 18 days. mAbs treatment seems to be safe and effective against the delta variant and its clinical manifestations.
Keyphrases
- sars cov
- end stage renal disease
- ejection fraction
- computed tomography
- respiratory syndrome coronavirus
- chronic kidney disease
- peritoneal dialysis
- magnetic resonance imaging
- gene expression
- magnetic resonance
- patient reported outcomes
- type diabetes
- intensive care unit
- respiratory failure
- combination therapy
- positron emission tomography
- smoking cessation
- weight loss
- patient reported
- acute respiratory distress syndrome
- circulating tumor cells
- image quality
- dual energy